S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Forecast, Price & News

$124.20
+7.36 (+6.30%)
(As of 06/2/2023 ET)
Compare
Today's Range
$116.51
$124.23
50-Day Range
$77.89
$120.48
52-Week Range
$49.17
$124.23
Volume
389,174 shs
Average Volume
241,300 shs
Market Capitalization
$3.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$134.00

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.9% Upside
$134.00 Price Target
Short Interest
Bearish
5.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.55mentions of Krystal Biotech in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$17.54 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.78) to ($1.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

668th out of 983 stocks

Biological Products, Except Diagnostic Industry

107th out of 164 stocks


KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company's wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $139.00
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $118.00
Why Shares of Krystal Biotech Are Rising Monday
See More Headlines

KRYS Price History

KRYS Company Calendar

Last Earnings
2/27/2023
Today
6/02/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
119
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$134.00
High Stock Price Forecast
$148.00
Low Stock Price Forecast
$118.00
Forecasted Upside/Downside
+14.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-139,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$18.98 per share

Miscellaneous

Free Float
21,414,000
Market Cap
$3.01 billion
Optionable
Not Optionable
Beta
0.83

Social Links


Key Executives

  • Krish S. Krishnan
    Chairman, President & Chief Executive Officer
  • Suma M. KrishnanSuma M. Krishnan
    Director, President-Research & Development
  • George Chen
    Manager-Information Technology & CSV
  • Trevor Parry
    Vice President-Research & Scientific Affairs
  • David Glynn
    General Counsel-Commercial & Compliance













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2023?

6 brokers have issued 12-month target prices for Krystal Biotech's shares. Their KRYS share price forecasts range from $118.00 to $148.00. On average, they expect the company's share price to reach $134.00 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 at the beginning of the year. Since then, KRYS stock has increased by 47.2% and is now trading at $116.61.
View the best growth stocks for 2023 here
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings data on Monday, February, 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.01.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (8.53%), Avoro Capital Advisors LLC (6.78%), BlackRock Inc. (6.66%), State Street Corp (3.98%), Credit Suisse AG (2.46%) and Pictet Asset Management SA (2.45%). Insiders that own company stock include Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $116.61.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $3.01 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.28) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 119 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -